#1 Clinical Trials Search in Europe

Tirofiban Hydrochloride Monohydrate

Tirofiban Hydrochloride Monohydrate, a medication used in certain heart conditions, is currently being studied in clinical trials for its potential benefits in treating acute ischemic stroke. This article explores the ATILA project, a clinical trial investigating the use of Tirofiban compared to aspirin in patients with acute ischemic stroke caused by tandem lesions. We’ll discuss the trial’s objectives, eligibility criteria, and potential outcomes, providing valuable insights into this promising area of stroke treatment research.

Table of Contents

What is Tirofiban Hydrochloride Monohydrate?

Tirofiban Hydrochloride Monohydrate is an active substance used in a medication called Agrastat[1]. It belongs to a class of drugs known as platelet aggregation inhibitors, which help prevent blood clots from forming[1]. Tirofiban is primarily used in the treatment of certain cardiovascular conditions, particularly those involving blood vessel blockages.

Medical Conditions Treated

Tirofiban is primarily used to treat acute ischemic stroke, a condition where blood flow to the brain is blocked, potentially causing damage to brain tissue[1]. Specifically, it’s being studied for use in patients with acute ischemic stroke due to a tandem lesion. A tandem lesion refers to a situation where there are two blockages: one in the neck (carotid) artery and another in a brain artery[1].

How Tirofiban Works

Tirofiban works by preventing platelets (small blood cells involved in clotting) from sticking together. This action helps to prevent the formation of blood clots or break down existing clots, which can improve blood flow to the brain in cases of ischemic stroke[1].

How Tirofiban is Administered

Tirofiban is given as a solution for intravenous infusion. This means it’s delivered directly into the bloodstream through a vein, usually in a hospital setting. The typical concentration is 50 micrograms per milliliter[1].

Current Clinical Trial: The ATILA Project

A clinical trial called the ATILA Project (Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion) is currently underway to study the effectiveness of Tirofiban compared to aspirin in treating acute ischemic stroke caused by tandem lesions[1].

Main Objectives of the Trial:

  • To assess the efficacy and safety of Tirofiban versus aspirin in patients with ischemic stroke due to tandem injury[1].
  • To determine the rate of reocclusion (re-blockage of blood vessels)[1].
  • To evaluate the rate of symptomatic bleeding, defined as any hemorrhagic transformation associated with a worsening of 4 or more points on the National Institutes of Health Stroke Scale[1].

Eligibility for the ATILA Trial

To participate in the ATILA trial, patients must meet certain criteria[1]:

  • Have acute ischemic stroke of the anterior territory secondary to a tandem lesion
  • Be indicated for thrombectomy treatment (a procedure to remove blood clots)
  • Need cervical stent placement
  • Be 18 years or older
  • Have an ASPECTS score (a measure of stroke severity) of 6 or higher

Potential Benefits of Tirofiban

The ATILA trial aims to determine if Tirofiban offers advantages over aspirin in treating acute ischemic stroke due to tandem lesions. Potential benefits being studied include[1]:

  • Reduced rate of reocclusion (re-blockage of blood vessels)
  • Improved functional outcomes at 90 days after treatment
  • Reduced need for rescue therapy during the procedure

Precautions and Exclusion Criteria

Certain conditions may prevent a patient from using Tirofiban or participating in the ATILA trial. These include[1]:

  • Documented allergy to Tirofiban or aspirin
  • History of low platelet count (platelets <100,000)
  • Current anticoagulant treatment
  • High risk of bleeding
  • Active peptic ulcer in the last 3 months
  • Severe allergy to contrast medium

It’s important to discuss your full medical history with your healthcare provider to determine if Tirofiban is appropriate for you.

Aspect Details
Trial Name ATILA Project (Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion)
Main Objective Assess efficacy and safety of tirofiban vs. aspirin in acute ischemic stroke patients with tandem lesions
Primary Outcomes Carotid reocclusion, platelet aggregation, symptomatic intracranial hemorrhage
Secondary Outcomes Functional prognosis at 90 days, rescue therapy rate, biomarker identification
Key Inclusion Criteria Adults with acute ischemic stroke due to tandem lesion, ASPECTS ≥6, need for thrombectomy and cervical stent
Key Exclusion Criteria Age <18, allergies to study drugs, high bleeding risk, severe comorbidities
Drug Information Tirofiban (AGRASTAT), 50 micrograms/ml solution for infusion, max daily dose 500 micrograms

FAQ

  • What is the main goal of the ATILA clinical trial? The main goal of the ATILA trial is to assess the effectiveness and safety of using Tirofiban compared to aspirin in patients with acute ischemic stroke caused by tandem lesions. The trial aims to determine the rate of reocclusion and symptomatic bleeding in these patients.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults (18 years or older) with acute ischemic stroke in the anterior brain region caused by a tandem lesion. They must have an indication for thrombectomy treatment and need cervical stent placement. Patients must also have an ASPECTS score of 6 or higher and provide signed informed consent.
  • What are some reasons why a person might not be eligible for this trial? Exclusion criteria include being under 18 years old, having intracranial occlusive arteriosclerotic disease, allergies to aspirin or Tirofiban, a history of low platelet count, current anticoagulant treatment, high bleeding risk, active peptic ulcer, or severe comorbidities. Patients with bilateral strokes or a modified Rankin scale score greater than 2 are also excluded.
  • How is Tirofiban administered in this clinical trial? Tirofiban is administered as an intravenous infusion. The medication used in the trial is AGRASTAT 50 micrograms/ml, which is a solution for infusion. The maximum daily dose is 500 micrograms, with a maximum total dose of 5283.4 micrograms over the treatment period.
  • What are the primary outcomes that researchers are looking at in this trial? The primary outcomes researchers are examining include carotid reocclusion, platelet aggregation phenomena, and symptomatic intracranial hemorrhage (sICH). They are also interested in the good functional prognosis of patients, defined as a score between 0-2 on the modified Rankin scale at 90 days after treatment.

Ongoing Clinical Trials on Tirofiban Hydrochloride Monohydrate

  • Study on Tirofiban and Aspirin for Patients with Acute Ischemic Stroke Due to Tandem Lesion

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Acute Ischemic Stroke: A sudden interruption of blood flow to part of the brain, causing a lack of oxygen and potentially leading to brain damage.
  • Tandem Lesion: In stroke, this refers to the presence of two blockages or narrowings in blood vessels, typically one in the neck (carotid artery) and another inside the brain.
  • Thrombectomy: A surgical procedure to remove a blood clot from a blood vessel.
  • ASPECTS: Alberta Stroke Program Early CT Score, a 10-point scoring system used to assess early ischemic changes on CT scans of the brain in patients with acute ischemic stroke.
  • Reocclusion: The recurrence of a blockage in a blood vessel after it has been initially cleared.
  • Symptomatic Intracranial Hemorrhage (sICH): Bleeding within the skull that causes neurological symptoms, often a complication of stroke treatment.
  • Modified Rankin Scale (mRS): A scale from 0 to 6 used to measure the degree of disability in patients who have had a stroke.
  • Endovascular Treatment: A minimally invasive procedure that accesses blood vessels through a small incision to treat vascular diseases.
  • Tirofiban: A medication that prevents platelets from sticking together, used to prevent blood clots in certain heart conditions and being studied for stroke treatment.
  • Aspirin: A common medication that helps prevent blood clots by reducing the stickiness of platelets.

References

  1. http://clinicaltrials.eu/trial/study-on-tirofiban-and-aspirin-for-patients-with-acute-ischemic-stroke-due-to-tandem-lesion/